PURPOSE: Complete androgen blockade (CAB) does not prolong overall survival (OS) in patients with castration refractory prostate cancer (CRPC). Although there is variable clinical benefit with second-line hormone manipulation. we do not know which patients might benefit the most. OBJECTIVES: To identify clinical predictors of benefit of complete androgen blockade. https://www.diegojavierfares.com/mega-pick-SA439-EF75-5-x-7-Embroidery-Machine-Hoop-mega-pick/